Trial Profile

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Eftilagimod alpha (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms INSIGHT-003

30 Jul 2025 According to an Immutep Limited media release, data from this trial are expected to be presented at a medical conference later in CY2025.
28 Jul 2025 According to an Immutep media release, data from this has been accepted for presentation , abstract to be presented at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany.
15 May 2025 Results (n=47) published in an Immutep Limited media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com